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A low level of cardiomyocyte turnover occurs in the adult mammalian heart, but the source of these new cells
remains unknown. Kimura et al., 2015 utilized a novel hypoxia-induced fate mapping system to identify a rare
population of adult cardiomyocytes undergoing cell-cycle entry and expansion in healthy adult hearts and
following ischemic injury.Anestablishedparadigm incardiovascular
regenerative medicine is that adult
mammalian cardiomyocytes have limited
proliferative capacity (Laflamme and
Murry, 2011). By examining the proportion
of carbon-14 integrated into cardiomyo-
cyte DNA from adults born during the nu-
clear testing era in the 1950s, Bergmann
et al. (2009) estimated that cardiomyocyte
turnover rate in humans declines with age
from 2% per year in the first decade of
life to less than 1%per year by the seventh
decade. Thus, the vast majority of adult
mammaliancardiomyocytesare terminally
differentiatedandunable to reenter thecell
cycle to replace cells lost during myocar-
dial injury (Figure 1). This is in contrast to
the remarkable cardiac regenerative po-
tential exhibited by lower vertebrates
such as zebrafish, as well as the lesser
regenerative capacity of the neonatal
mammalian heart (Porrello et al., 2011;
Poss et al., 2002; Sturzu et al., 2015). The
low cardiomyocyte turnover described by
Bergmann et al. (2009) suggests that asmall population of proliferative cells may
be present in the adult heart; however,
the identity of these cells (e.g., progeni-
tors, immature cardiomyocytes/cardio-
myoblasts, or specialized cardiomyocytes
with proliferative potential) remains
elusive. In a recent study, Kimura et al.
(2015) reported that rare adult proliferative
cardiomyocytes are enrichedwithin a hyp-
oxic environment and can expand in the
presence of myocardial ischemic injury.
In order to search for this rare popula-
tion of proliferating myocytes, Kimura
et al. (2015) devised a novel system to
track hypoxic cells. In an earlier study,
the authors found that high oxygen levels
may be responsible for the cell-cycle ar-
rest observed in adult mammalian cardio-
myocytes (Kimura et al., 2015; Puente
et al., 2014). Thus, by logical exten-
sion, a hypoxic environment may induce
greater cardiomyocyte proliferation as
seen in an actively dividing fetal heart. In
this study, an elegant CreER-LoxP mouse
model was utilized to label hypoxic cardi-omyocytes expressing Hif-1a, a master
regulator of the hypoxic stress response.
Specifically, the CreER recombinase
was fused to the oxygen-dependent
degradation (ODD) domain of Hif-1a,
restricting CreER activity to hypoxic con-
ditions. Thus, when driven by either a
ubiquitous CAG promoter or a cardio-
myocyte-specific a-myosin heavy chain
promoter, this CreER-ODD construct
fluorescently labeled hypoxic cardiomyo-
cytes in adult mice carrying a ROSA26-
flox-stop-flox-tdTomato cassette. The
authors confirmed that the Cre-labeled
cardiomyocytes are hypoxic by showing
the co-localization of the hypoxia detector
pimonidazole with tdTomato+ cardio-
myocytes. When these mice were sub-
jected to global hypoxia and then injected
with tamoxifen to activate CreER-medi-
ated recombination, the authors saw
a significant increase in tdTomato+
cardiomyocytes throughout the heart,
suggesting that the CreER-ODD system
can accurately label hypoxic cells.eptember 1, 2015 ª2015 Elsevier Inc. 365
Figure 1. Cardiomyocyte Proliferative Capacity during Mammalian Development
Significant cardiomyocyte proliferation occurs during embryonic development. This capacity diminishes
rapidly in the neonatal heart following birth. Adult cardiomyocytes have a limited ability to undergo cell
division. Kimura et al. (2015) identified a rare population of small hypoxic cardiomyocytes in the adult heart
with enhanced proliferative capacity.
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the tdTomato+ hypoxic myocytes were
smaller and invested by fewer capillaries,
suggesting that these specialized cardio-
myocytes experience lower oxygen levels
due to a reduced blood supply.
Having established a way to mark
hypoxic cardiomyocytes, the authors
investigatedwhether thesehypoxiccardio-
myocytes exhibit enhanced proliferative
ability by lineage tracing tdTomato+ cells
following tamoxifen-induced Cre recombi-
nation driven by the ubiquitous CAG pro-
moter. Remarkably, they found a 7-fold in-
crease in tdTomato+ cardiomyocytes a
month after labeling when compared to
the number of tdTomato+ cardiomyocytes
seen at 1week. The authors estimated that
the rate of tdTomato+ cardiomyocyte turn-
over was roughly 1% per year, consistent
with the Bergmann et al. (2009) study.
Clusters of tdTomato+ cardiomyocytes
were also observed, suggesting clonal
expansion. When these studies were repli-
cated using the cardiomyocyte-specific
a-myosin heavy chain promoter coupled
with theCreER-ODDconstruct, theauthors
were again able to demonstrate that these
cardiomyocytes are labeled by tdTomato,
are smaller, are surrounded by fewer capil-
laries, and exhibit less oxidative DNA dam-
age suggestive of their hypoxic state.
When isolated using laser capture micro-
dissection and analyzed for gene expres-
sion using RNA sequencing, tdTomato+
myocytes showed upregulation of Hif-1a
expression and other regulators that
induceHif-1a. Reciprocally, negative regu-
lators of cell-cycle progression such as
CDK inhibitors were downregulated. In
both transgenic mouse models, the
tdTomato+ cardiomyocytes significantly
increase in number at 2 months following366 Cell Metabolism 22, September 1, 2015 ªinitial tamoxifen injection. These cardio-
myocytes also exhibited a significant in-
crease in the expression of Ki67, a marker
of cell-cycle activity, and incorporation of
the DNA analog BrdU. Furthermore,
tdTomato+ cardiomyocytes increased in
number following induced myocardial
infarction, suggesting that these cells may
enhance cell turnover after ischemic injury.
The results presented by Kimura et al.
(2015) demonstrate the existence of a
rare population of hypoxic cardiomyo-
cytes with enhanced proliferative capacity
in the adultmammalian heart. In particular,
the CreER-ODD system represents a
unique method of detecting oxygen ten-
sion in a tissue bed with a cell-type-spe-
cific readout.Given the limited cardiomyo-
cyte division in the adult mammalian
heart during normal aging and following
ischemic injury, it is intriguing that low ox-
ygen tension, the cause for cardiomyocyte
death during myocardial infarction, would
also drive cardiomyocyte proliferation. As
with any paradigm-changing study, more
questions are raised than answered. For
example, increased cardiomyocyte prolif-
eration has not been reported in chroni-
cally ischemic adult human hearts (Senyo
et al., 2013). This raises the question: is
there a degree of hypoxia that is ‘‘just
right’’ for triggering this enhanced cardi-
omyocyte proliferation? Also, given the
metabolic shift from oxidative phosphory-
lation to anaerobic glycolysis in cells
undergoing hypoxia, could there be spe-
cific metabolic intermediates in cardio-
myocytes that act as signaling mediators
for cell-cycle entry? Furthermore, it would
be informative to know the downstream
targets of Hif-1a in cardiomyocytes, as
Hif-1a has been well-recognized to influ-
ence tumor angiogenesis (Weidemann2015 Elsevier Inc.and Johnson, 2008). Finally, in order to uti-
lize these hypoxia-responsive cells for
regenerative therapy, it will be important
to determine how this rare population of
cardiomyocytes retains or acquires its
proliferative capacity while the majority of
adult cardiomyocytes do not.
In addition to introducing a rare cell pop-
ulation that can generate new cardiomyo-
cytes, this study raises the exciting possi-
bility that hypoxia may trigger metabolic
alterations that enhance cell-cycle entry.
The race is on to see whether the same
process can promote cell renewal in other
poorly regenerative organs—such as the
brain, pancreas, or kidney—and the key
metabolic intermediates involved.ACKNOWLEDGMENTS
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